LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Listă Acțiuni・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Închisă

27.75 -2.7

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

27.69

Maxim

28.17

Indicatori cheie
By Trading Economics
Venit	43M 13M
Vânzări	29M 107M
EPS	0.25
Marjă de profit	12.139
Angajați	524
EBITDA	16M 8.2M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+122.21% upside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	18M 1.5B
Deschiderea anterioară	30.45
Închiderea anterioară	27.75

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

27.895 / 30.16 Suport & Rezistență

Immunocore Holdings PLC ADR Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 mai 2026, 23:53 UTC

Achiziții, Fuziuni, Preluări

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mai 2026, 22:47 UTC

Acțiuni populare

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mai 2026, 22:16 UTC

Achiziții, Fuziuni, Preluări

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mai 2026, 22:00 UTC

Principalele dinamici ale pieței

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mai 2026, 18:09 UTC

Principalele dinamici ale pieței

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mai 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mai 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17 mai 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mai 2026, 23:07 UTC

Achiziții, Fuziuni, Preluări

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mai 2026, 23:06 UTC

Achiziții, Fuziuni, Preluări

UOB: Share Sale Agreements Entered With Singland Properties

17 mai 2026, 23:05 UTC

Achiziții, Fuziuni, Preluări

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mai 2026, 22:31 UTC

Achiziții, Fuziuni, Preluări

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mai 2026, 22:31 UTC

Achiziții, Fuziuni, Preluări

Prudential PLC to Acquire Stake for $389 Million

17 mai 2026, 22:30 UTC

Achiziții, Fuziuni, Preluări

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mai 2026, 16:27 UTC

Achiziții, Fuziuni, Preluări

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mai 2026, 15:26 UTC

Achiziții, Fuziuni, Preluări

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mai 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 22:17 UTC

Achiziții, Fuziuni, Preluări

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:59 UTC

Achiziții, Fuziuni, Preluări

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mai 2026, 21:50 UTC

Achiziții, Fuziuni, Preluări

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 20:19 UTC

Acțiuni populare

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mai 2026, 19:41 UTC

Achiziții, Fuziuni, Preluări

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mai 2026, 18:35 UTC

Câștiguri

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Comparație

Modificare preț

Immunocore Holdings PLC ADR Așteptări

Obiectiv de preț

By TipRanks

122.21% sus

Prognoză pe 12 luni

Medie 62.33 USD 122.21%

Maxim 100 USD

Minim 33 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruImmunocore Holdings PLC ADR - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

10 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 10 analiști care au acordat evaluări ale acțiunilor Immunocore Holdings PLC ADR - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

27.895 / 30.16Suport & Rezistență

Recent bearish events outweigh bullish events.

There is one bearish event.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.